GLP-1 receptor agonistGLP-1 AgonistsVerified Match
Semaglutide
A long-acting GLP-1 receptor agonist. FDA-approved as Ozempic/Wegovy (injectable) and Rybelsus (oral) for type 2 diabetes and obesity. Achieves 15-17% weight loss. Available in oral 25mg formulation since 2026.
weight-lossblood-sugar-controlappetite-suppressioncardiovascular-protectionFDA-approved
3D Structure
3D Structure
4113.58 Da
Lab Tested
Yes
Harmful Ingredients
0
Contaminants
None
Tested Purity
--
Batch Consistency
No batch data
Mass Spec Profile
ESI-MS (computed)
Batch Info
Latest Batch#G2025011105
Total Tests52
Unique Vendors51
Vendor Comparison
| Vendor | Status |
|---|---|
N Next Day Peptides | Pending |
N Next Day Peptides | Pending |
B Bulk Peptide Supply | Verified |
N Nexaph | Verified |
S Shanghai Sigma Audley SSA | Verified |
Analysis Summary
Purity Standard
No purity dataLab Reports
52 reports on file
Summary
A long-acting GLP-1 receptor agonist. FDA-approved as Ozempic/Wegovy (injectable) and Rybelsus (oral) for type 2 diabetes and obesity. Achieves 15-17% weight loss. Available in oral 25mg formulation s…